Search results for "Retrospective studies"

showing 10 items of 3098 documents

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCO…

2020

BackgroundSkin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion from clinical trials, the ICI treatment efficacy is poorly investigated in these patients. The present study analyzed the ICI treatment outcome in advanced patients with skin cancer with a concomitant hematological malignancy.MethodsThis retrospective multicenter study included patients who were treated with ICI for locally advanced or metastatic melanoma (MM), cutaneous squamous cell carcinoma (cS…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtySkin Neoplasms2435medicine.medical_treatmentChronic lymphocytic leukemiaImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicinemelanomaImmunology and AllergyHumans1506Immune Checkpoint InhibitorsRC254-282AgedRetrospective StudiesPharmacologyClinical/Translational Cancer ImmunotherapyMerkel cell carcinomabusiness.industryMelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyMiddle Agedmedicine.diseaseSurvival AnalysisLymphoma030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantHematologic NeoplasmsMolecular MedicineFemaleImmunotherapySkin cancerbusinessProgressive diseaseJournal for Immunotherapy of Cancer
researchProduct

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospectiv…

2017

Natural Killer cells (NK) are lymphocytes with the potential to recognize and lyse cells which escaped T-cell mediated lysis due to their aberrant HLA expression profiles. Killer cell immunoglobulin-like receptors (KIR) influence NK-cell activity by mediation of activating or inhibitory signals upon interaction with HLA-C (C1, C2) ligands. Therefore, absence of ligands for donor inhibitory KIRs following hematopoietic stem cell transplantation (HSCT) may have an influence on its outcome. Previous studies showed that C1 negative patients have a decreased HSCT outcome. Our study, based on a cohort of 200 C1-negative patients, confirmed these findings for the endpoints: overall survival (OS: H…

0301 basic medicineOncologyMaleMyeloidCell Transplantationmedicine.medical_treatmentlcsh:MedicineHematopoietic stem cell transplantationNK cellsLigandsCohort StudiesWhite Blood Cells0302 clinical medicineMathematical and Statistical TechniquesReceptors KIRCell SignalingComplement C1Animal CellsMedicine and Health SciencesBlood and Lymphatic System ProceduresMembrane Receptor SignalingReceptorlcsh:ScienceBone Marrow TransplantationMultidisciplinaryT CellsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationMiddle AgedImmune Receptor Signaling3. Good healthKiller Cells Naturalmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsCohortPhysical SciencesFemaleCellular TypesUnrelated DonorsStatistics (Mathematics)Research ArticleSignal TransductionAdultmedicine.medical_specialtyAdolescentImmune CellsImmunologySurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesYoung AdultInternal medicinemedicineConfidence IntervalsHumansClinical significanceddc:610Statistical MethodsAgedRetrospective StudiesTransplantationBlood Cellsbusiness.industrylcsh:RBiology and Life SciencesRetrospective cohort studyCell BiologyMultivariate analysis; Stem cell transplantation; T cells; Bone marrow transplantation; NK cells; Hematopoietic stem cell transplantation; Immune receptor signalingTransplantation030104 developmental biologyImmunologyMultivariate Analysislcsh:QbusinessMathematics030215 immunologyStem Cell TransplantationPLoS ONE
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct

Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure

2018

STUDY QUESTION: Is endometrial recurrent implantation failure (RIF) only a matter of an asynchronous (displaced) window of implantation (WOI), or could it also be a pathological (disrupted) WOI? SUMMARY ANSWER: Our predictive results demonstrate that both displaced and disrupted WOIs exist and can present independently or together in the same RIF patient. WHAT IS KNOWN ALREADY: Since 2002, many gene expression signatures associated with endometrial receptivity and RIF have been described. Endometrial transcriptomics prediction has been applied to the human WOI in two previous studies. One study describes endometrial RIF to be the result of a temporal displacement of the WOI. The other indic…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceprecision medicineBiologyEndometrial tissue03 medical and health sciencesEndometrium0302 clinical medicineImplantation failuretranscriptomic predictorsInternal medicinemedicinepolycyclic compoundsHumansendometrial asynchronyEmbryo Implantationendometrial pathologyendometriumPathologicalRetrospective Studiesrecurrent implantation failure030219 obstetrics & reproductive medicineGene Expression ProfilingRehabilitationConfoundingObstetrics and GynecologyRetrospective cohort studyEmbryo TransferPenetranceGene expression profilinggene expression signatures030104 developmental biologyReproductive Medicinemachine learning predictorswindow of implantation displacementFemaleTranscriptomeInfertility Femaletranscriptomic taxonomy
researchProduct

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes

2021

There is a growing need for biomarkers to predict therapeutic outcome in Crohn's disease (CD).The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn's disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calcul…

0301 basic medicineOncologymedicine.medical_specialtyNeutrophilsClinical BiochemistryDisease03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineDrug DiscoverymedicineHumansLymphocytesRetrospective StudiesPharmacologyBiological ProductsCrohn's diseasebusiness.industryfungiOutcome measuresPrognosismedicine.diseaseInflammatory biomarkers030104 developmental biology030220 oncology & carcinogenesisMucosal healingbusinessBiomarkersExpert Opinion on Biological Therapy
researchProduct

Precision medicine in the adjuvant treatment of gastric cancer

2018

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancermedicine.diseasePrecision medicine03 medical and health sciences030104 developmental biology0302 clinical medicineText miningOncologyChemotherapy AdjuvantGastrectomyStomach Neoplasms030220 oncology & carcinogenesisInternal medicinemedicineHumansPrecision MedicinebusinessAdjuvantRetrospective StudiesThe Lancet Oncology
researchProduct